ADPRS and ovarian carcinoma: Here, we explore the potential impact of the combined therapeutic approach involving ARH3 and PARG inhibition on cancer cells, focusing on ovarian cancer cells because of the crucial role of PARylation on ovarian cancer resistance to chemotherapeutics [9,35,[38], [39], [40], [41], [42], [43]].